2025-09-14 - Analysis Report
Okay, here's an analysis of Recursion Pharmaceuticals (RXRX), based on the provided information.

**Report on Recursion Pharmaceuticals Inc. (RXRX)**

Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to discover and develop novel therapeutics.

**1. Performance vs. S&P 500 (VOO)**

*   **Cumulative Return:** RXRX: -46.84%, VOO: 44.94%
*   **Divergence:**
    *   Current Divergence: -86.5
    *   Relative Divergence: 3.2

    This indicates RXRX has significantly underperformed the S&P 500 over the period. The relative divergence of 3.2 suggests that this underperformance is near the worst end of its historical range compared to the S&P 500.

*   **Alpha/Beta Analysis:**

| Year       | CAGR | MDD  | Alpha  | Beta | Cap(B) |
|------------|------|------|--------|------|--------|
| 2021-2023  | 5.0% | 73.6% | -4.0%  | 0.0  | 4.3    |
| 2022-2024  | 0.0% | 73.6% | -26.0% | 0.0  | 3.0    |
| 2023-2025  | 5.0% | 73.6% | -50.0% | 0.0  | 2.1    |

    *   **CAGR:** Shows inconsistent growth rates.
    *   **MDD:** A very high Maximum Drawdown (73.6%) indicates significant volatility and risk.
    *   **Alpha:** The consistently negative Alpha suggests underperformance relative to its benchmark on a risk-adjusted basis. The Alpha is becoming increasingly negative over time, indicating worsening relative performance.
    *   **Beta:** A Beta of 0.0 suggests that the stock's price is independent of the broad market index.
    *   **Cap(B):** Market capitalization is decreasing over time, which could reflect investor concern.

**2. Recent Price Action**

*   **Current Price:** 4.83
*   **Price Change:** -0.41 (-0.41% decrease from the previous close of 4.85), indicating a slight negative recent movement.
*   **Moving Averages:**
    *   5-day MA: 4.708
    *   20-day MA: 4.8447
    *   60-day MA: 5.3152

    The stock price is currently above the 5-day MA but below the 20-day and 60-day MAs, suggesting short-term upward momentum but longer-term downward pressure.

**3. Technical Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.3233 (Low Risk)
*   **RSI:** 45.60 (Neutral)
*   **PPO:** 0.4877 (Potentially bullish if it continues to rise)
*   **Hybrid Signal:** cash_1%_Buy 90% of cash (414 shares - Safe - MRI:0.32) (Cash Ratio: 1% on 2025-09-12)
*   **Recent Relative Divergence Change (20-day):** -1.5 (Short-term downward trend compared to the S&P 500)
*   **Expected Return:** -960.2% (This is an exceptionally negative projected return compared to the S&P 500, indicating significant perceived risk or potential for underperformance.)

**4. Recent News & Significant Events**

*   **Insider Selling:** A recent sale of shares worth $471,000 by a company insider could raise concerns about the company's prospects.
*   **Equity Milestone:** Rallybio received $12.5 million equity milestone from Recursion, suggesting ongoing partnerships and potential revenue streams.
*   **Investment Analysis:** Articles suggest mixed opinions on the stock's past performance and potential future growth, including mentions of its AI capabilities and backing from Nvidia.
*   **Pipeline Expansion:** Acquisition of REV102 expands the rare disease pipeline, potentially diversifying revenue streams.
*   **Investor Conferences:** Participation in upcoming investor conferences indicates proactive investor relations.

**4-2) Analyst Opinions**

*   **Consensus:** Hold (Mean: 2.62)
*   **Target Price:** Average: $6.47, High: $10.00, Low: $3.00. The wide range in target prices indicates uncertainty among analysts.
*   **Rating Changes:** No recent changes were provided.

**5. Recent Earnings Analysis**

| 날짜       | EPS    | 매출      |
|------------|--------|-----------|
| 2025-08-05 | -0.41  | 0.02 B$   |
| 2025-05-05 | -0.5   | 0.01 B$   |
| 2024-11-06 | -0.34  | 0.03 B$   |
| 2024-08-08 | -0.4   | 0.01 B$   |
| 2025-08-05 | -0.4   | 0.01 B$   |

*   The company is consistently reporting negative Earnings Per Share (EPS), indicating unprofitability.
*   Revenue generation is low.

**6. Financial Information**

*   **Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-06-30 | $0.02B   | -5.54%        |
| 2025-03-31 | $0.01B   | -47.31%       |
| 2024-12-31 | $0.00B   | -183.62%      |
| 2024-09-30 | $0.03B   | 53.69%        |
| 2024-06-30 | $0.01B   | 36.14%        |

*   While revenue fluctuates, the profit margins are highly volatile and often negative, demonstrating a lack of consistent profitability.

*   **Capital and Profitability:**

| Quarter    | Equity   | ROE       |
|------------|----------|-----------|
| 2025-06-30 | $0.92B   | -18.70%   |
| 2025-03-31 | $0.93B   | -21.68%   |
| 2024-12-31 | $1.03B   | -17.29%   |
| 2024-09-30 | $0.52B   | -18.27%   |
| 2024-06-30 | $0.58B   | -16.69%   |

*   Equity has fluctuated.
*   Return on Equity (ROE) is consistently negative, indicating that the company is not generating profits from its equity.

**7. Summary Analysis**

RXRX is a high-risk investment. The company has significantly underperformed the S&P 500 and exhibits high volatility.

*   **Financials:** The company is currently unprofitable, with inconsistent revenue and negative profit margins and ROE.
*   **Technicals:** The stock is trading below its 20-day and 60-day moving averages, indicating short-term upward momentum but longer-term downward pressure.
*   **Sentiment:** Analyst consensus is "Hold" but with a wide range of price targets. Recent insider selling could be a negative signal. The exceptionally negative expected return indicates that the model projects significant risk or potential for underperformance relative to the S&P 500.
*   **Catalysts:** The company's focus on AI and expansion of its drug pipeline are potential growth catalysts, but these are not yet translating into financial performance.
*   **Risks:** High volatility, negative profitability, significant underperformance relative to the market, and the need to successfully develop and commercialize its drug pipeline.
